Beta Bionics, Inc. (BBNX) insider buying and SEC filings
Beta Bionics, Inc. · CIK 1674632
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Beta Bionics, Inc
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.5M
Planned sales (10b5-1)
$3.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 27, 2026 | Planned (10b5-1) | Mike Mensinger (Chief Product Officer) sold 2,650 shares at $22.00 ($58K), marked as a 10b5-1 plan trade. Holdings down 1% to 174,740 shares. | SEC filing Filed Oct 29, 2026, 4:22 PM ET |
| Oct 26, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 821 shares at $20.00 ($16K), marked as a 10b5-1 plan trade. Holdings down 1% to 54,513 shares. | SEC filing Filed Oct 28, 2026, 4:03 PM ET |
| Oct 14, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 775 shares at about $17.35 ($13K), marked as a 10b5-1 plan trade. Holdings down 1% to 55,334 shares. | SEC filing Filed Oct 16, 2026, 4:10 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 370 shares at about $18.96 ($7K), marked as a 10b5-1 plan trade. Holdings down 1% to 56,109 shares. | SEC filing Filed Oct 5, 2026, 5:11 PM ET |
| Sep 22, 2026 | Planned (10b5-1) | Christy Jones (Director) sold 6,430 shares at $23.00 ($148K), marked as a 10b5-1 plan trade. Holdings down 25% to 19,564 shares. | SEC filing Filed Sep 23, 2026 |
| Sep 9, 2026 | Planned (10b5-1) Amended filing | Mark Hopman (Chief Commercial Officer) sold 35,994 shares at $18.46 ($664K), marked as a 10b5-1 plan trade. Holdings down 29% to 88,033 shares. This amends a filing from Sep 10. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Mike Mensinger (Chief Product Officer) sold 2,650 shares at $22.00 ($58K), marked as a 10b5-1 plan trade. Holdings down 1% to 177,390 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 30,779 shares at about $20.13 ($620K), marked as a 10b5-1 plan trade. Holdings down 35% to 56,479 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 775 shares at $15.52 ($12K), marked as a 10b5-1 plan trade. Holdings down 1% to 86,382 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 3, 2026 | Planned (10b5-1) | Sean Saint (CEO and Director) sold 5,641 shares at about $20.08 ($113K), marked as a 10b5-1 plan trade. Holdings down 1% to 398,429 shares. | SEC filing Filed Sep 4, 2026 |
| Sep 2, 2026 | Sale | Steven Jon Russell (Chief Medical Officer) sold 4,221 shares at about $19.11 ($81K). Holdings down 2% to 169,628 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 3, 2026 |
| Sep 2, 2026 | Sale | Sean Saint (CEO and Director) sold 16,867 shares at about $19.11 ($322K). Holdings down 4% to 404,070 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 3, 2026 |
| Sep 2, 2026 | Sale | Stephen Feider (CFO) sold 6,675 shares at about $19.11 ($128K). Holdings down 4% to 159,378 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 3, 2026 |
| Sep 2, 2026 | Sale | Mike Mensinger (Chief Product Officer) sold 4,375 shares at about $19.11 ($84K). Holdings down 2% to 180,040 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 3, 2026 |
| Sep 2, 2026 | Sale | Mark Hopman (Chief Commercial Officer) sold 5,327 shares at about $19.11 ($102K). Holdings down 4% to 124,027 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 3, 2026 |
| Jun 26–29, 2026 | Planned (10b5-1) Amended filing | Stephen Feider (CFO) sold 10,000 shares between Jun 26 and Jun 29 at about $17.04 ($170K), marked as a 10b5-1 plan trade. Holdings down 6% to 166,053 shares. This amends a filing from Jun 30. | SEC filing Filed Jul 2, 2026 |
| Jun 24, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 1,258 shares at about $15.01 ($19K), marked as a 10b5-1 plan trade. Holdings down 1% to 129,354 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 24, 2026 | Planned (10b5-1) | Christy Jones (Director) sold 1,406 shares at $15.00 ($21K), marked as a 10b5-1 plan trade. Holdings down 5% to 25,994 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 275 shares at $12.31 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 130,612 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Christy Jones (Director) sold 2,811 shares at $14.00 ($39K), marked as a 10b5-1 plan trade. Holdings down 9% to 27,400 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 2, 2026 | Sale | Steven Jon Russell (Chief Medical Officer) sold 4,222 shares at about $12.61 ($53K). Holdings down 2% to 173,849 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 3, 2026 |
| Jun 2, 2026 | Sale | Sean Saint (CEO and Director) sold 16,872 shares at about $12.61 ($213K). Holdings down 4% to 420,937 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 3, 2026 |
| Jun 2, 2026 | Sale | Stephen Feider (CFO) sold 6,676 shares at about $12.61 ($84K). Holdings down 4% to 166,053 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 3, 2026 |
| Jun 2, 2026 | Sale | Mike Mensinger (Chief Product Officer) sold 4,378 shares at about $12.61 ($55K). Holdings down 2% to 184,415 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 3, 2026 |
| Jun 2, 2026 | Sale | Mark Hopman (Chief Commercial Officer) sold 5,329 shares at about $12.61 ($67K). Holdings down 4% to 130,887 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 3, 2026 |
| May 21, 2026 | Planned (10b5-1) | Christy Jones (Director) sold 1,998 shares at $9.95 ($20K), marked as a 10b5-1 plan trade. Holdings down 13% to 13,246 shares. | SEC filing Filed May 26, 2026 |
| May 21–22, 2026 | Planned (10b5-1) | Adam Lezack (Director) sold 1,998 shares in 2 share classes between May 21 and May 22 at about $10.58 ($21K), marked as a 10b5-1 plan trade. Holdings of Common Stock down 8% to 11,432 shares. | SEC filing Filed May 26, 2026 |
| Dec 2, 2025 | Sale | Steven Jon Russell (Chief Medical Officer) sold 1,025 shares at $29.34 ($30K). Holdings down 1% to 178,071 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 16, 2026 |
| Dec 2–4, 2025 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 2,917 shares between Dec 2, 2025 and Dec 4, 2025 at about $30.27 ($88K), marked as a 10b5-1 plan trade. Holdings down 2% to 136,216 shares. | SEC filing Filed Mar 16, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | Mark Hopman (Chief Commercial Officer) sold 353 shares at $11.57 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 139,133 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 2, 2026 | Sale | Steven Jon Russell (Chief Medical Officer) sold 1,026 shares at about $12.36 ($13K). Holdings down 1% to 179,096 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Sean Saint (CEO and Director) sold 3,384 shares at about $12.36 ($42K). Holdings down 1% to 437,809 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Stephen Feider (CFO) sold 1,428 shares at about $12.36 ($18K). Holdings down 1% to 172,729 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Mike Mensinger (Chief Product Officer) sold 1,064 shares at about $12.36 ($13K). Holdings down 1% to 188,793 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Mark Hopman (Chief Commercial Officer) sold 834 shares at about $12.36 ($10K). Holdings down 1% to 139,486 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Mike Mensinger (Chief Product Officer) sold 2,200 shares at about $30.10 ($66K), marked as a 10b5-1 plan trade. Holdings down 3% to 80,752 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Stephen Feider (CFO) sold 20,000 shares at about $29.53 ($591K), marked as a 10b5-1 plan trade. Holdings down 32% to 42,614 shares. | SEC filing Filed Jan 5, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Mike Mensinger (Chief Product Officer) sold 7,800 shares at about $29.61 ($231K), marked as a 10b5-1 plan trade. Holdings down 9% to 82,952 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 2, 2025 | Sale | Sean Saint (CEO and Director) sold 3,278 shares at $29.34 ($96K). Holdings down 3% to 97,924 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 4, 2025 |
| Dec 2, 2025 | Sale | Stephen Feider (CFO) sold 1,427 shares at $29.34 ($42K). Holdings down 3% to 42,614 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 4, 2025 |
| Dec 2, 2025 | Sale | Mike Mensinger (Chief Product Officer) sold 1,063 shares at $29.34 ($31K). Holdings down 1% to 90,752 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 4, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Adam Lezack (Director) sold 1,406 shares at about $29.55 ($42K), marked as a 10b5-1 plan trade. Holdings down 14% to 8,435 shares. | SEC filing Filed Dec 2, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Maria Palasis (Director) sold 1,406 shares at about $29.55 ($42K), marked as a 10b5-1 plan trade. Holdings down 14% to 8,435 shares. | SEC filing Filed Dec 2, 2025 |
| Oct 31, 2025 | Planned (10b5-1) | Adam Lezack (Director) sold 1,406 shares at about $26.87 ($38K), marked as a 10b5-1 plan trade. Holdings down 13% to 9,841 shares. | SEC filing Filed Nov 5, 2025 |
| Oct 31, 2025 | Planned (10b5-1) | Maria Palasis (Director) sold 1,406 shares at about $26.91 ($38K), marked as a 10b5-1 plan trade. Holdings down 13% to 9,841 shares. | SEC filing Filed Nov 5, 2025 |
19 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow BBNX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.